RaaS Group Research Report
RaaS Group has released its research report on Anatara Lifesciences (ASX:ANR) ahead of the ASX Small and Mid-Cap Conference 2020.
“Going with the gut”
Please open the attached PDF to view the report.
Pitt Street Research Report
Pitt Street Research has released its latest research and valuation report on Anatara Lifesciences (ASX:ANR). The report provided a $1.09/share base case and $3.20/share optimistic case valuation range.
“Detach upside remains”
Please open the attached PDF to view the report.
PAC Partners Research Report
PAC Partners released its latest research report on Anatara Lifesciences (ANR). The report provided a SPEC BUY rating and a price target of $0.90 per share.
“Life after Zoetis”
Please open the attached PDF to view the report.
PAC Partners Research Report
PAC Partners released its latest research report on Anatara Lifesciences (ANR). The report maintained a BUY rating and a price target of $1.40 per share.
“World IBD Day – Sunday 19 May – ANR offers natural treatment”
Please open the attached PDF to view the report.
Pitt Street Research Report
Pitt Street Research Valuation Report – “Following the gut”
Pitt Street Research has released its follow-up research and valuation report on Anatara Lifesciences (ANR). The report valued Anatara at $1.34 base case and $3.61 optimistic case using a probability-weighted DCF valuation approach.
Please click on the PDF to view the report.
PAC Partners Research Report
PAC Partners released its latest research report on Anatara Lifesciences (ANR). The report maintained a BUY rating and a price target of $1.40 per share.
“On track for GaRP supplement partner”
Please open the attached PDF to view the report.
PAC Partners Research Report
PAC Partners released its latest research report on Anatara Lifesciences (ANR). The report maintained a BUY rating and a price target of $1.40 per share.
“Solid short term milestones”
Please open the attached PDF to view the report.
Latest PAC Partners Research Report
PAC Partners released its latest research report on Anatara Lifesciences (ANR). The report maintained a BUY rating and a price target of $1.40 per share.
“Restore human gut health with GaRP”
Please open the attached PDF to view the report.